Skip to content
10-K

Annual Report

Spero Therapeutics, Inc. SPRO

0001193125-26-126192

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 20, 2026 57.89M sh
Shares Diluted FY 2025 · Dec 31, 2025 59.04M sh
Shares Diluted FY 2025 · Dec 31, 2024 54.04M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$12.62M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$23.44M
Cash And Equivalents FY 2025 · Dec 31, 2025 $40.27M
Cash And Equivalents FY 2025 · Dec 31, 2024 $52.89M
Stockholders Equity FY 2025 · Dec 31, 2025 $59.02M
Stockholders Equity FY 2025 · Dec 31, 2024 $46.12M
Stockholders Equity FY 2025 · Dec 31, 2023 $106.89M
Current Liabilities FY 2025 · Dec 31, 2025 $8.87M
Current Liabilities FY 2025 · Dec 31, 2024 $49.07M
Total Liabilities FY 2025 · Dec 31, 2025 $9.9M
Total Liabilities FY 2025 · Dec 31, 2024 $64.42M
Current Assets FY 2025 · Dec 31, 2025 $67.29M
Current Assets FY 2025 · Dec 31, 2024 $107.28M
Total Assets FY 2025 · Dec 31, 2025 $68.92M
Total Assets FY 2025 · Dec 31, 2024 $110.54M
Eps Diluted FY 2025 · Dec 31, 2025 $0.15
Eps Diluted FY 2025 · Dec 31, 2024 −$1.27
Eps Basic FY 2025 · Dec 31, 2025 $0.15
Eps Basic FY 2025 · Dec 31, 2024 −$1.27
Sga Expense FY 2025 · Dec 31, 2025 $21.18M
Sga Expense FY 2025 · Dec 31, 2024 $23.7M
Rd Expense FY 2025 · Dec 31, 2025 $38.47M
Rd Expense FY 2025 · Dec 31, 2024 $96.76M
Net Income FY 2025 · Dec 31, 2025 $8.57M
Net Income FY 2025 · Dec 31, 2024 −$68.57M
Operating Income FY 2025 · Dec 31, 2025 $6.31M
Operating Income FY 2025 · Dec 31, 2024 −$73.36M
Revenue FY 2025 · Dec 31, 2025 $12.59M
Revenue FY 2025 · Dec 31, 2024 $371K